Putting Tumours in Context

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2002 Mar 20

PMID 11900251

Citations 862

Authors

M J Bissell

D Radisky

Affiliations

Soon will be listed here.

Abstract

The interactions between cancer cells and their micro- and macroenvironment create a context that promotes tumour growth and protects it from immune attack. The functional association of cancer cells with their surrounding tissues forms a new 'organ' that changes as malignancy progresses. Investigation of this process might provide new insights into the mechanisms of tumorigenesis and could also lead to new therapeutic targets.

Citing Articles

Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancer.

Yang M, Nebozhyn M, Schell M, Gandhi N, Pflieger L, Loboda A BMC Cancer. 2025; 25(1):441.

PMID: 40075322 PMC: 11899100. DOI: 10.1186/s12885-025-13829-2.

Regulation of ER stress-induced apoptotic and inflammatory responses via YAP/TAZ-mediated control of the TRAIL-R2/DR5 signaling pathway.

El Yousfi Y, Fernandez-Farran F, Oliver F, Lopez-Rivas A, Yerbes R Cell Death Discov. 2025; 11(1):42.

PMID: 39904986 PMC: 11794427. DOI: 10.1038/s41420-025-02335-w.

Breast pericytes: a newly identified driver of tumor cell proliferation.

Del Toro K, Licon-Munoz Y, Crabtree W, Oper T, Robbins C, Hines W Front Oncol. 2025; 14():1455484.

PMID: 39741968 PMC: 11685225. DOI: 10.3389/fonc.2024.1455484.

Pathological features of the differentiation landscape in esophageal squamous cell cancer and their correlations with prognosis.

Deng J, Zhang L, Wang Z, Li B, Xiang J, Ma L Front Oncol. 2024; 14:1442212.

PMID: 39711958 PMC: 11659131. DOI: 10.3389/fonc.2024.1442212.

Mechanisms of endocrine resistance in hormone receptor-positive breast cancer.

Gao Y, Yu Y, Zhang M, Yu W, Kang L Front Oncol. 2024; 14:1448687.

PMID: 39544302 PMC: 11560879. DOI: 10.3389/fonc.2024.1448687.

References

Mudry R, Fortney J, York T, Hall B, Gibson L . Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood. 2000; 96(5):1926-32. View

Michigami T, Shimizu N, Williams P, Niewolna M, Dallas S, Mundy G . Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood. 2000; 96(5):1953-60. View

Moennikes O, Buchmann A, Willecke K, Traub O, Schwarz M . Hepatocarcinogenesis in female mice with mosaic expression of connexin32. Hepatology. 2000; 32(3):501-6. DOI: 10.1053/jhep.2000.16598. View

Vu T, Werb Z . Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000; 14(17):2123-33. DOI: 10.1101/gad.815400. View

Raghavan S, Bauer C, Mundschau G, Li Q, Fuchs E . Conditional ablation of beta1 integrin in skin. Severe defects in epidermal proliferation, basement membrane formation, and hair follicle invagination. J Cell Biol. 2000; 150(5):1149-60. PMC: 2175239. DOI: 10.1083/jcb.150.5.1149. View

Coussens L, Tinkle C, Hanahan D, Werb Z . MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000; 103(3):481-90. PMC: 2843102. DOI: 10.1016/s0092-8674(00)00139-2. View

Shain K, Landowski T, Dalton W . The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opin Oncol. 2000; 12(6):557-63. DOI: 10.1097/00001622-200011000-00008. View

Friedman S, Maher J, BISSELL D . Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology. 2000; 32(6):1403-8. DOI: 10.1053/jhep.2000.20243. View

Mitchell R, Bucala R . Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol. 2000; 10(5):359-66. DOI: 10.1006/scbi.2000.0328. View

10.

Szabowski A, Andrecht S, Kolbus A, Schorpp-Kistner M, Fusenig N, Angel P . c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell. 2000; 103(5):745-55. DOI: 10.1016/s0092-8674(00)00178-1. View

11.

Chang Y, Di Tomaso E, McDonald D, Jones R, Jain R, Munn L . Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A. 2000; 97(26):14608-13. PMC: 18966. DOI: 10.1073/pnas.97.26.14608. View

12.

Moreno A, Villar M, Camara C, Luque R, Cespon C, Gonzalez-Porque P . Interleukin-6 dimers produced by endothelial cells inhibit apoptosis of B-chronic lymphocytic leukemia cells. Blood. 2001; 97(1):242-9. DOI: 10.1182/blood.v97.1.242. View

13.

Abe R, Peng T, Sailors J, Bucala R, Metz C . Regulation of the CTL response by macrophage migration inhibitory factor. J Immunol. 2001; 166(2):747-53. DOI: 10.4049/jimmunol.166.2.747. View

14.

Sanz-Rodriguez F, Hidalgo A, Teixido J . Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood. 2001; 97(2):346-51. DOI: 10.1182/blood.v97.2.346. View

15.

Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M . Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 2001; 61(2):445-51. View

16.

Mitsiades N, Yu W, Poulaki V, Tsokos M, Stamenkovic I . Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 2001; 61(2):577-81. View

17.

Maria D, Ribeiro O, Pizzocaro K, De Franco M, Cabrera W, Starobinas N . Resistance to melanoma metastases in mice selected for high acute inflammatory response. Carcinogenesis. 2001; 22(2):337-42. DOI: 10.1093/carcin/22.2.337. View

18.

BEATTY G, Paterson Y . IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol. 2001; 166(4):2276-82. DOI: 10.4049/jimmunol.166.4.2276. View

19.

Frank B, Rossall J, Caughey G, Fang K . Mast cell tissue inhibitor of metalloproteinase-1 is cleaved and inactivated extracellularly by alpha-chymase. J Immunol. 2001; 166(4):2783-92. DOI: 10.4049/jimmunol.166.4.2783. View

20.

Hidalgo M, Eckhardt S . Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001; 93(3):178-93. DOI: 10.1093/jnci/93.3.178. View